Head-to-head evidence
DBPR108 vs HRX0701
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
DBPR108
Developed by CSPC Pharmaceutical Group
NCT04161430 · Phase 3 · completed
In this randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial, 766 patients with type 2 diabetes were randomized to DBPR108, sitagliptin, or placebo. DBPR108 reduced HbA1c significantly more than placebo at 24 weeks, with a treatment difference whose confidence interval excluded no effect.
HRX0701
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05415644 · Phase 1 · completed
This is a randomized, blinded, crossover comparison against the reference formulation, which is a sound design for its purpose, but it measures only drug levels in the blood rather than a diabetes outcome, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DBPR108's landscape · HRX0701's landscape